Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
Beijing Children's Hospital, Capital Medical University, China National Clinical Research Center of Respiratory Diseases, National Center for Children's Health, Beijing, China
1 other identifier
observational
1,100
1 country
1
Brief Summary
To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for children. According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. Demographic data and clinical information were collected, and subgroup analysis was designed to explore the relationship between them and medical expenses and clinical treatment burden.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 15, 2022
CompletedFirst Submitted
Initial submission to the registry
October 12, 2023
CompletedFirst Posted
Study publicly available on registry
December 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedDecember 4, 2025
December 1, 2025
3.2 years
October 12, 2023
December 2, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
hospitalization costs
hospitalization costs,pharmcost,testcost,testcost
duration of hospital stay
Secondary Outcomes (1)
hospital day
duration of hospital stay
Interventions
uninvolved
Eligibility Criteria
According to the seven administrative regions of China, namely Northeast, North, Northwest, Southwest, Central, South and East China, 1-3 children's medical institutions were selected from each region, and the cases of bronchiolitis or pneumonia admitted to hospitals and diagnosed as RSV positive by etiology during January 1, 2017 to December 31, 2021 were selected. A total of 11 hospitals were selected, each with 100 children, a total of 1100 cases
You may qualify if:
- Hospitalized patients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia
You may not qualify if:
- Inpatients under 18 years of age with an etiological diagnosis of RSV-positive bronchiolitis or pneumonia are excluded from any of the following criteria:
- Pneumonia occurring 48 hours after hospitalization;
- Combined with bronchial foreign body;
- Participants in clinical trials of drugs or medical devices;
- Not complete personal and family history and other relevant information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Children's Hospital
Beijing, Beijing Municipality, 100045, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
October 12, 2023
First Posted
December 4, 2025
Study Start
October 15, 2022
Primary Completion
December 12, 2025
Study Completion
December 30, 2025
Last Updated
December 4, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share